Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 in Combination With Capecitabine or Capecitabine Monotherapy, in Unresectable, Locally Advanced or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated:  9/25/2017
ImClone Investigational Site
mi
from
Los Angeles, CA
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 in Combination With Capecitabine or Capecitabine Monotherapy, in Unresectable, Locally Advanced or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated: 9/25/2017
ImClone Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 in Combination With Capecitabine or Capecitabine Monotherapy, in Unresectable, Locally Advanced or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated:  9/25/2017
ImClone Investigational Site
mi
from
Jacksonville, FL
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 in Combination With Capecitabine or Capecitabine Monotherapy, in Unresectable, Locally Advanced or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated: 9/25/2017
ImClone Investigational Site
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 in Combination With Capecitabine or Capecitabine Monotherapy, in Unresectable, Locally Advanced or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated:  9/25/2017
ImClone Investigational Site
mi
from
Augusta, GA
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 in Combination With Capecitabine or Capecitabine Monotherapy, in Unresectable, Locally Advanced or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated: 9/25/2017
ImClone Investigational Site
mi
from
Augusta, GA
Click here to add this to my saved trials
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 in Combination With Capecitabine or Capecitabine Monotherapy, in Unresectable, Locally Advanced or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated:  9/25/2017
ImClone Investigational Site
mi
from
Chicago, IL
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 in Combination With Capecitabine or Capecitabine Monotherapy, in Unresectable, Locally Advanced or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated: 9/25/2017
ImClone Investigational Site
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 in Combination With Capecitabine or Capecitabine Monotherapy, in Unresectable, Locally Advanced or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated:  9/25/2017
ImClone Investigational Site
mi
from
Indianapolis, IN
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 in Combination With Capecitabine or Capecitabine Monotherapy, in Unresectable, Locally Advanced or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated: 9/25/2017
ImClone Investigational Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 in Combination With Capecitabine or Capecitabine Monotherapy, in Unresectable, Locally Advanced or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated:  9/25/2017
ImClone Investigational Site
mi
from
Baton Rouge, LA
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 in Combination With Capecitabine or Capecitabine Monotherapy, in Unresectable, Locally Advanced or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated: 9/25/2017
ImClone Investigational Site
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 in Combination With Capecitabine or Capecitabine Monotherapy, in Unresectable, Locally Advanced or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated:  9/25/2017
ImClone Investigational Site
mi
from
Stony Brook, NY
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 in Combination With Capecitabine or Capecitabine Monotherapy, in Unresectable, Locally Advanced or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated: 9/25/2017
ImClone Investigational Site
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 in Combination With Capecitabine or Capecitabine Monotherapy, in Unresectable, Locally Advanced or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated:  9/25/2017
ImClone Investigational Site
mi
from
Washington, NC
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 in Combination With Capecitabine or Capecitabine Monotherapy, in Unresectable, Locally Advanced or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated: 9/25/2017
ImClone Investigational Site
mi
from
Washington, NC
Click here to add this to my saved trials
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 in Combination With Capecitabine or Capecitabine Monotherapy, in Unresectable, Locally Advanced or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated:  9/25/2017
ImClone Investigational Site
mi
from
Columbus, OH
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 in Combination With Capecitabine or Capecitabine Monotherapy, in Unresectable, Locally Advanced or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated: 9/25/2017
ImClone Investigational Site
mi
from
Columbus, OH
Click here to add this to my saved trials
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 in Combination With Capecitabine or Capecitabine Monotherapy, in Unresectable, Locally Advanced or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated:  9/25/2017
ImClone Investigational Site
mi
from
San Antonio, TX
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 in Combination With Capecitabine or Capecitabine Monotherapy, in Unresectable, Locally Advanced or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated: 9/25/2017
ImClone Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 in Combination With Capecitabine or Capecitabine Monotherapy, in Unresectable, Locally Advanced or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated:  9/25/2017
ImClone Investigational Site
mi
from
Richmond, VA
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 in Combination With Capecitabine or Capecitabine Monotherapy, in Unresectable, Locally Advanced or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated: 9/25/2017
ImClone Investigational Site
mi
from
Richmond, VA
Click here to add this to my saved trials
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 in Combination With Capecitabine or Capecitabine Monotherapy, in Unresectable, Locally Advanced or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated:  9/25/2017
ImClone Investigational Site
mi
from
Spokane, WA
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 in Combination With Capecitabine or Capecitabine Monotherapy, in Unresectable, Locally Advanced or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated: 9/25/2017
ImClone Investigational Site
mi
from
Spokane, WA
Click here to add this to my saved trials
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 in Combination With Capecitabine or Capecitabine Monotherapy, in Unresectable, Locally Advanced or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated:  9/25/2017
ImClone Investigational Site
mi
from
Calgary,
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 in Combination With Capecitabine or Capecitabine Monotherapy, in Unresectable, Locally Advanced or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated: 9/25/2017
ImClone Investigational Site
mi
from
Calgary,
Click here to add this to my saved trials
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 in Combination With Capecitabine or Capecitabine Monotherapy, in Unresectable, Locally Advanced or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated:  9/25/2017
ImClone Investigational Site
mi
from
The Bronx, NY
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 in Combination With Capecitabine or Capecitabine Monotherapy, in Unresectable, Locally Advanced or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Status: Enrolling
Updated: 9/25/2017
ImClone Investigational Site
mi
from
The Bronx, NY
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Arizona Center for Cancer Care - Peoria
mi
from
Peoria, AZ
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Arizona Center for Cancer Care - Peoria
mi
from
Peoria, AZ
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Arizona Cancer Center at University of Arizona Health Sciences Center
mi
from
Tucson, AZ
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Arizona Cancer Center at University of Arizona Health Sciences Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Arizona Oncology - Tucson
mi
from
Tucson, AZ
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Arizona Oncology - Tucson
mi
from
Tucson, AZ
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Veterans Affairs Medical Center - Long Beach
mi
from
Long Beach, CA
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Veterans Affairs Medical Center - Long Beach
mi
from
Long Beach, CA
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
University of California Davis Cancer Center
mi
from
Sacramento, CA
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
University of California Davis Cancer Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Radiological Associates of Sacramento Medical Group, Incorporated
mi
from
Sacramento, CA
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Radiological Associates of Sacramento Medical Group, Incorporated
mi
from
Sacramento, CA
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
CCOP - Christiana Care Health Services
mi
from
Newark, DE
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
CCOP - Christiana Care Health Services
mi
from
Newark, DE
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Baptist Cancer Institute - Jacksonville
mi
from
Jacksonville, FL
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Baptist Cancer Institute - Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Baptist-South Miami Regional Cancer Program
mi
from
Miami, FL
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Baptist-South Miami Regional Cancer Program
mi
from
Miami, FL
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Florida Cancer Center - Palatka
mi
from
Palatka, FL
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Florida Cancer Center - Palatka
mi
from
Palatka, FL
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Piedmont Hospital
mi
from
Atlanta, GA
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Piedmont Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Rush University Medical Center
mi
from
Chicago, IL
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
OSF St. Francis Medical Center
mi
from
Peoria, IL
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
OSF St. Francis Medical Center
mi
from
Peoria, IL
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Center for Cancer Care at Goshen General Hospital
mi
from
Goshen, IN
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Center for Cancer Care at Goshen General Hospital
mi
from
Goshen, IN
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Methodist Cancer Center at Methodist Hospital
mi
from
Indianapolis, IN
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Methodist Cancer Center at Methodist Hospital
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Nebraska Medical Center
mi
from
Omaha, NE
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Nebraska Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
St. Barnabas Medical Center Cancer Center
mi
from
Livingston, NJ
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
St. Barnabas Medical Center Cancer Center
mi
from
Livingston, NJ
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
New York Oncology Hematology, PC at Albany Regional Cancer Care
mi
from
Albany, NY
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
New York Oncology Hematology, PC at Albany Regional Cancer Care
mi
from
Albany, NY
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Jean and Milton Cooper Cancer Center at Summa Akron City Hospital
mi
from
Akron, OH
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Jean and Milton Cooper Cancer Center at Summa Akron City Hospital
mi
from
Akron, OH
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Adena Regional Medical Center
mi
from
Chillicothe, OH
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Adena Regional Medical Center
mi
from
Chillicothe, OH
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Cleveland Clinic Taussig Cancer Center
mi
from
Cleveland, OH
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Cleveland Clinic Taussig Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Southwest General Health Center
mi
from
Middleburg Heights, OH
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Southwest General Health Center
mi
from
Middleburg Heights, OH
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Oklahoma University Cancer Institute
mi
from
Oklahoma City, OK
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Oklahoma University Cancer Institute
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Willamette Valley Cancer Center - Eugene
mi
from
Eugene, OR
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Willamette Valley Cancer Center - Eugene
mi
from
Eugene, OR
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Providence Cancer Center at Providence Portland Medical Center
mi
from
Portland, OR
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Providence Cancer Center at Providence Portland Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Rosenfeld Cancer Center at Abington Memorial Hospital
mi
from
Abington, PA
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Rosenfeld Cancer Center at Abington Memorial Hospital
mi
from
Abington, PA
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Bryn Mawr Hospital
mi
from
Bryn Mawr, PA
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Bryn Mawr Hospital
mi
from
Bryn Mawr, PA
Click here to add this to my saved trials
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated:  9/25/2017
Regional Cancer Center - Erie
mi
from
Erie, PA
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Status: Enrolling
Updated: 9/25/2017
Regional Cancer Center - Erie
mi
from
Erie, PA
Click here to add this to my saved trials